Please note: The information displayed on this page might be outdated.
4SC AG: (Xetra: VSC-DE; Mkt Cap $USM75.90) an epigenetic focused company developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s lead compound, Resminostat, is focused on Cutaneous T Cell Lymphoma but has unpartnered assets for Hodkins Lymphona, Colorectal Cancer, and HCC. Additional products are 4SC-202, an epigenetic anti-cancer compound that has completed Phase I clinical trial for the treatment of hematological tumors; and 4SC-205, an anti-cancer compound, which has completed Phase I clinical trial for the treatment of solid tumors.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Hematology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Website:
Address:
Fraunhoferstrasse 22
Planegg-Martinsried, 82152
Germany

Company Participants at Oktoberfest 2019 Wall Street "On Tap"

  • Anna Niedl, Unknown

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Ownership data is sourced through FactSet.